Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
Pfizer
Aulos Bioscience, Inc.
Essen Biotech
enGene, Inc.
Hoffmann-La Roche
Second Life Therapeutics
Ocellaris Pharma, Inc.
Tyra Biosciences, Inc
Memorial Sloan Kettering Cancer Center